IRCCS Eugenio Medea
medea.itTotal trials
105
Active
41
Phase 3
1
Total enrollment
7,324
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Optical Genome Mapping | — | — | — | — | — | 2 | |
| methyphenidate | — | — | — | — | — | 1 |
Next readouts
- 2026-12
- 2026-12
Top conditions
- Cerebral Palsy13
- Acquired Brain Injury10
- Autism Spectrum Disorder8
- Parent-Child Relations4
- Developmental Dyslexia4
- Muscular Dystrophies4
- Epilepsy4
- Neurodevelopmental Disorders4
Frequently asked questions about IRCCS Eugenio Medea
- How many clinical trials does IRCCS Eugenio Medea have on ClinicalTrials.gov?
- IRCCS Eugenio Medea is listed as the lead sponsor on 105 clinical trials in ClinicalTrials.gov, 41 of which are currently active (recruiting, enrolling, or ongoing).
- How many of IRCCS Eugenio Medea's trials are in Phase 3?
- 1 of IRCCS Eugenio Medea's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does IRCCS Eugenio Medea focus on?
- IRCCS Eugenio Medea's most-studied conditions on ClinicalTrials.gov are Cerebral Palsy, Acquired Brain Injury, Autism Spectrum Disorder, Parent-Child Relations, Developmental Dyslexia.
- When are IRCCS Eugenio Medea's next clinical trial readouts?
- IRCCS Eugenio Medea has 2 upcoming primary-completion readouts tracked here; the soonest is “Expanding NGS Data with Optical Genome Mapping (OGM)”, expected around 2026-12.